Ohcanbohtosat - Alberto D’Angelo

  • Čájehuvvo 1 - 11 / 11
Aiddostahte ozu
  1. 1
    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

    Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma Dahkki Navid Sobhani, Matteo Pittacolo, Alberto D’Angelo, Giovanni Marchegiani

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer Dahkki Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Tobias Otto

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Pré-impressão
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy

    MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy Dahkki Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D’Angelo, Daniele Lavacchi, Franco Roviello, Karol Połom

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Advances in anti-BRAF therapies for lung cancer

    Advances in anti-BRAF therapies for lung cancer Dahkki Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

    Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy Dahkki Marianna Sirico, Alberto D’Angelo, Caterina Gianni, Chiara Casadei, Filippo Merloni, Ugo De Giorgi

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

    Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer Dahkki Giandomenico Roviello, Alberto D’Angelo, Roberto Petrioli, Franco Roviello, Fabio Cianchi, Stefania Nobili, Enrico Mini, Daniele Lavacchi

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption

    AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption Dahkki Navid Sobhani, Praveen Neeli, Alberto D’Angelo, Matteo Pittacolo, Marianna Sirico, Ilaria Camilla Galli, Giandomenico Roviello, Gabriella Nesi

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer

    Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer Dahkki Navid Sobhani, Anna Ianza, Alberto D’Angelo, Giandomenico Roviello, Fabiola Giudici, Marina Bortul, Fabrizio Zanconati, Cristina Bottin, Daniele Generali

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

    Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer Dahkki Navid Sobhani, Alberto D’Angelo, Matteo Pittacolo, Giandomenico Roviello, Anna Miccoli, Silvia Paola Corona, Ottavia Bernocchi, Daniele Generali, Tobias Otto

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use

    Methylene Blue—Current Knowledge, Fluorescent Properties, and Its Future Use Dahkki Tomasz Cwalinski, Wojciech Połom, Luigi Marano, Giandomenico Roviello, Alberto D’Angelo, Natalia Cwalina, Marcin Matuszewski, Giandomenico Roviello, Janusz Jaśkiewicz, Karol Połom

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies

    Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies Dahkki Alberto D’Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Revisão
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: